Last updated: 15:31
Vital Chemtech Limited is a leading manufacturer of phosphorus-based chemicals for various industries such as lifesciences, crop care, specialty chemicals, textile auxiliaries, dyes, pigments and plastic additives. It was founded in 1993 by Mr. Vipul Jatashanker Bhatt and Mrs. Sangeeta Vipul Bhatt, who are the promoters and directors of the company. The company has a state-of-the-art, integrated manufacturing complex in PCPIR region of Dahej, Gujarat, with PLC and SCADA operated systems and ZLD (Zero Liquid Discharge) facility to ensure minimum...Read More
Vital Chemtech Limited is a leading manufacturer of phosphorus-based chemicals for various industries such as lifesciences, crop care, specialty chemicals, textile auxiliaries, dyes, pigments and plastic additives. It was founded in 1993 by Mr. Vipul Jatashanker Bhatt and Mrs. Sangeeta Vipul Bhatt, who are the promoters and directors of the company. The company has a state-of-the-art, integrated manufacturing complex in PCPIR region of Dahej, Gujarat, with PLC and SCADA operated systems and ZLD (Zero Liquid Discharge) facility to ensure minimum emissions and waste generation. The company is certified with ISO 9001:2015, ISO 45001:2018 and ISO 14001:2015 from Bureau Veritas to maintain highest quality, environmental and safety practices. The company produces Phosphorus Trichloride (PCl3), Phosphorus Oxychloride (POCl3), Phosphorus Pentachloride (PCl5), Phosphorus Pentoxide (P2O5), Poly Phosphoric Acid (PPA) and Phosphorus Pentasulfide (P2S5) for its customers across India and abroad. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹158 Cr.
Stock P/E 38.8
P/B 1.7
Current Price ₹65.8
Book Value ₹ 38.5
Face Value 10
52W High ₹75.1
Dividend Yield 0%
52W Low ₹ 35.4
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|
| Net Sales | 58 | 117 | 98 | 134 | |
| Other Income | 0 | 0 | 3 | 2 | |
| Total Income | 58 | 117 | 102 | 136 | |
| Total Expenditure | 46 | 102 | 98 | 123 | |
| Operating Profit | 12 | 15 | 4 | 13 | |
| Interest | 0 | 1 | 1 | 2 | |
| Depreciation | 1 | 2 | 3 | 5 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | |
| Profit Before Tax | 11 | 11 | -0 | 6 | |
| Provision for Tax | 3 | 3 | 1 | 2 | |
| Profit After Tax | 8 | 8 | -1 | 4 | |
| Adjustments | 0 | 0 | 0 | 0 | |
| Profit After Adjustments | 8 | 8 | -1 | 4 | |
| Adjusted Earnings Per Share | 4.7 | 3.4 | -0.5 | 1.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 37% | 32% | 0% | 0% |
| Operating Profit CAGR | 225% | 3% | 0% | 0% |
| PAT CAGR | 0% | -21% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -10% | -12% | NA% | NA% |
| ROE Average | 5% | 6% | 18% | 18% |
| ROCE Average | 7% | 7% | 11% | 11% |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Shareholder's Funds | 15 | 90 | 84 | 92 |
| Minority's Interest | 0 | 0 | 0 | 1 |
| Borrowings | 21 | 22 | 16 | 40 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 1 |
| Total Current Liabilities | 45 | 25 | 37 | 48 |
| Total Liabilities | 81 | 138 | 137 | 182 |
| Fixed Assets | 17 | 21 | 43 | 68 |
| Other Non-Current Assets | 3 | 24 | 37 | 38 |
| Total Current Assets | 61 | 93 | 58 | 75 |
| Total Assets | 81 | 138 | 137 | 182 |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 6 | 31 | 0 |
| Cash Flow from Operating Activities | -13 | -8 | 14 | 6 |
| Cash Flow from Investing Activities | 1 | -26 | -35 | -30 |
| Cash Flow from Financing Activities | 18 | 58 | -9 | 25 |
| Net Cash Inflow / Outflow | 6 | 24 | -30 | 0 |
| Closing Cash & Cash Equivalent | 6 | 31 | 0 | 1 |
| # | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Earnings Per Share (Rs) | 4.7 | 3.36 | -0.54 | 1.69 |
| CEPS(Rs) | 5.12 | 4.33 | 0.56 | 3.77 |
| DPS(Rs) | 0 | 0.5 | 0.5 | 0 |
| Book NAV/Share(Rs) | 8.7 | 37.41 | 35.21 | 38.47 |
| Core EBITDA Margin(%) | 20 | 12.66 | 0.2 | 8.43 |
| EBIT Margin(%) | 19.24 | 10.8 | 0.91 | 6.26 |
| Pre Tax Margin(%) | 18.39 | 9.84 | -0.36 | 4.64 |
| PAT Margin (%) | 13.71 | 6.9 | -1.33 | 3.03 |
| Cash Profit Margin (%) | 14.92 | 8.88 | 1.35 | 6.74 |
| ROA(%) | 9.72 | 7.35 | -0.95 | 2.54 |
| ROE(%) | 54.03 | 15.45 | -1.5 | 4.6 |
| ROCE(%) | 21.75 | 14.89 | 0.78 | 6.7 |
| Receivable days | 264.37 | 125.02 | 143.97 | 117.58 |
| Inventory Days | 57.36 | 35.21 | 48.49 | 35.82 |
| Payable days | 264.94 | 90.83 | 92.16 | 99.82 |
| PER(x) | 0 | 22.86 | 0 | 29.62 |
| Price/Book(x) | 0 | 2.05 | 2.02 | 1.3 |
| Dividend Yield(%) | 0 | 0.65 | 0.7 | 0 |
| EV/Net Sales(x) | 0.64 | 1.56 | 1.99 | 1.25 |
| EV/Core EBITDA(x) | 3.13 | 12.22 | 55.38 | 12.54 |
| Net Sales Growth(%) | 0 | 102.63 | -15.82 | 36.26 |
| EBIT Growth(%) | 0 | 13.77 | -92.9 | 837.03 |
| PAT Growth(%) | 0 | 1.94 | -116.17 | 411.44 |
| EPS Growth(%) | 0 | -28.49 | -116.17 | 411.46 |
| Debt/Equity(x) | 2.49 | 0.32 | 0.31 | 0.52 |
| Current Ratio(x) | 1.34 | 3.66 | 1.58 | 1.56 |
| Quick Ratio(x) | 1.14 | 3.13 | 1.24 | 1.28 |
| Interest Cover(x) | 22.89 | 11.22 | 0.72 | 3.86 |
| Total Debt/Mcap(x) | 0 | 0.16 | 0.15 | 0.4 |
| # | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Promoter | 73.43 | 73.43 | 73.43 | 73.43 | 73.43 | 73.43 | 73.43 |
| FII | 3.62 | 0.78 | 0.56 | 0.16 | 1.78 | 1.78 | 1.62 |
| DII | 1.48 | 0.63 | 0 | 0 | 0 | 0 | 0 |
| Public | 21.47 | 25.16 | 26.01 | 26.41 | 24.79 | 24.79 | 24.95 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Promoter | 1.76 | 1.76 | 1.76 | 1.76 | 1.76 | 1.76 | 1.76 |
| FII | 0.09 | 0.02 | 0.01 | 0 | 0.04 | 0.04 | 0.04 |
| DII | 0.04 | 0.02 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.51 | 0.6 | 0.62 | 0.63 | 0.59 | 0.59 | 0.6 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2.4 | 2.4 | 2.4 | 2.4 | 2.4 | 2.4 | 2.4 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
